{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:26:38Z","timestamp":1760081198687,"version":"3.41.2"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Sickle cell disease is an autosomal recessive disorder characterized by the presence of sickle hemoglobin that leads to chronic hemolysis and vaso-occlusive crisis. After decades of limited therapy options, crizanlizumab is a humanized monoclonal antibody approved by the Food and Drug Administration (FDA) in 2019 for sickle cell-related pain crises for patients 16 years of age and above. Although rare, infusion-related reactions, including painful crises, occurred in 3% as per the package insert. However, the data on how to deal with such reactions and about further treatment outcomes are limited as most patients stopped crizanlizumab after the reaction. Herein, we report the good outcome of 13 doses of crizanlizumab in a 19-year-old female patient with sickle cell disease on hydroxyurea, despite experiencing a severe infusion-related painful crisis during the second infusion. Additional benefits of crizanlizumab, in this case, were preventing new episodes of acute chest syndrome, quitting chronic narcotics use, and a remarkable improvement in quality of life and overall performance.<\/jats:p>","DOI":"10.3389\/fmed.2022.1048571","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T10:31:35Z","timestamp":1669717895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report"],"prefix":"10.3389","volume":"9","author":[{"given":"Awni","family":"Alshurafa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"journal-title":"Sickle Cell Crisis.","year":"2022","author":"Borhade","key":"B1"},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/16078454.2020.1714113","article-title":"Distribution of sickle cell disease and assessment of risk factors based on transcranial Doppler values in the Gulf region.","volume":"25","author":"Wali","year":"2020","journal-title":"Hematol Amst Neth."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e2017037","DOI":"10.4084\/MJHID.2017.037","article-title":"Liver Iron Content (LIC) in Adults with Sickle Cell Disease (SCD): correlation with serum ferritin and liver enzymes concentrations in Trasfusion Dependent (TD-SCD) and Non-Transfusion Dependent (NT-SCD) Patients.","volume":"9","author":"Yassin","year":"2017","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1073\/pnas.052522799","article-title":"Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm.","volume":"99","author":"Turhan","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"key":"B5","doi-asserted-by":"publisher","first-page":"102424","DOI":"10.1016\/j.bcmd.2020.102424","article-title":"Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: a standardized microfluidic assessment.","volume":"83","author":"Man","year":"2020","journal-title":"Blood Cells Mol Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/00062752-200203000-00003","article-title":"Sickle cell vaso-occlusion: multistep and multicellular paradigm.","volume":"9","author":"Frenette","year":"2002","journal-title":"Curr Opin Hematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.exphem.2020.08.008","article-title":"Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials.","volume":"92","author":"Ali","year":"2020","journal-title":"Exp Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.2147\/JPR.S278285","article-title":"P-selectin blockade in the treatment of painful vaso-occlusive crises in sickle cell disease: a spotlight on crizanlizumab.","volume":"14","author":"Karki","year":"2021","journal-title":"J Pain Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1182\/blood-2021-144636","article-title":"L-glutamine and crizanlizumab for adults with sickle cell disease (SCD) in qatar: a cost effectiveness analysis.","volume":"138","author":"Adel","year":"2021","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease.","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1097\/HS9.0000000000000604","article-title":"The European medicines agency review of crizanlizumab for the prevention of recurrent vaso-occlusive crises in patients with sickle cell disease.","volume":"5","author":"Delgado","year":"2021","journal-title":"HemaSphere."},{"key":"B12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2147\/JBM.S191423","article-title":"Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date.","volume":"10","author":"Riley","year":"2019","journal-title":"J Blood Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1182\/blood-2021-152362","article-title":"Rare cases of infusion-related reactions (IRRs) presenting as pain events during or after crizanlizumab infusion in patients (Pts) with Sickle Cell Disease (SCD): a systematic evaluation of post-marketing (PM) reports.","volume":"138","author":"Kanter","year":"2021","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1182\/blood-2021-154355","article-title":"Crizanlizumab-associated painful febrile reaction in sickle cell disease patients.","volume":"138","author":"Li","year":"2021","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"E338","DOI":"10.1002\/ajh.26002","article-title":"Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease.","volume":"95","author":"Karkoska","year":"2020","journal-title":"Am J Hematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"931924","DOI":"10.3389\/fmed.2022.931924","article-title":"Case report: safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease.","volume":"9","author":"Alshurafa","year":"2022","journal-title":"Front Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"931925","DOI":"10.3389\/fmed.2022.931925","article-title":"Real-World data on the efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients.","volume":"9","author":"Elenga","year":"2022","journal-title":"Front Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1048571\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T10:31:37Z","timestamp":1669717897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1048571\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":17,"alternative-id":["10.3389\/fmed.2022.1048571"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1048571","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"article-number":"1048571"}}